Gender disparity in systemic lupus erythematosus, thoughts after the 8th international congress on systemic lupus erythematosus, Shanghai, China, 2007

Journal of Clinical Rheumatology

Volumn 14, Issue 3, 2008, Pages 185-187

  Lahita, Robert G ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEWARK BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; AUTOANTIBODY; BROMOCRIPTINE; CD40 LIGAND; DNA ANTIBODY; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ETHINYLESTRADIOL; FULVESTRANT; INTERLEUKIN 6; MEDROXYPROGESTERONE; NORETHISTERONE; PRASTERONE; PROLACTIN; PROLACTIN RECEPTOR; QUINAGOLIDE; TESTOSTERONE; ANDROGEN;

ALBUMINURIA; ANTIBODY PRODUCTION; B LYMPHOCYTE; CHINA; CLINICAL TRIAL; CONFERENCE PAPER; CYTOKINE RELEASE; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG SAFETY; ESTROGEN BLOOD LEVEL; GENETIC PREDISPOSITION; HORMONAL REGULATION; HORMONAL THERAPY; HORMONE SUBSTITUTION; HUMAN; HYPERPROLACTINEMIA; LOW DRUG DOSE; LUPUS LIKE SYNDROME; LYMPHOCYTE FUNCTION; MENOPAUSE; MICROADENOMA; MODULATION; NONHUMAN; PREGNANCY; PREMENOPAUSE; PRIORITY JOURNAL; PROTEINURIA; SEX DIFFERENCE; SYSTEMIC LUPUS ERYTHEMATOSUS; TESTOSTERONE BLOOD LEVEL; TH1 CELL; TH2 CELL; ANIMAL; FEMALE; IMMUNOLOGY; MALE; MOUSE; ORGANIZATION; REVIEW;

ANDROGENS; ANIMALS; CONGRESSES AS TOPIC; ESTROGENS; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MICE; PROLACTIN; RECEPTORS, ESTROGEN; SEX FACTORS;

EID: 48249139500     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e3181778ce0     Document Type: Conference Paper

References (32)

1. Lupus: Proceedings of 8th International Congress on SLE. Shanghai, China 2007, Lupus, 2007;16:1-268(abstract suppl).
2. Lahita RG. Sex and age in systemic lupus erythematosus. In: Lahita RG, ed. Systemic Lupus Erythematosus. 1st ed. New York: John Wiley and Sons; 1986:523-539.
3. Lahita RG. Sex hormones and systemic lupus erythematosus. Rheum Dis Clin North Am. 2000;26:951-968.
4. Walker SE. Impaired hypothalamic function, prolactinomas, and autoimmune diseases. J Rheumatol. 2006;33:1036-1037.
5. Lockshin MC, Gabriel S, Zakeri Z, et al. Gender, biology and human disease: report of a conference. Lupus. 1999;8:335-338.
6. Costenbader KH, Feskanich D, Stampfer MJ, et al. Reproductive and menopausal factors and risk of systemic lupus erythematosus. Arthritis Rheum. 2007;56:1251-1262.
7. Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-433.
8. Sanchez-Guerrero J, Liang MH, Karlson EW, et al. Past use of oral contraceptives and the risk of developing systemic lupus erythematosus. Ann Intern Med. 1995;122:430-433.
9. Rider V, Foster RT, Evans M, et al. Gender differences in autoimmune diseases: estrogen increases calcineurin expression in systemic lupus erythematosus. Clin Immunol Immunopathol. 1998;89:171-180.
10. Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters threshholds for B cell apoptosis and activation. J Clin Investig. 2002;109:1625-1633.
11. Kassi EN, Vlachoyiannopoulos PG, Moutsopoulos HM, et al. Molecular analysis of estrogen receptor alpha and beta in lupus patients. Eur J Clin Invest. 2001;31:86-93.
12. Kassi EN, Vlachoyiannopoulos PG, Kominakis A, et al. Estrogen receptor alpha gene polymorphism and systemic lupus erythematosus: a possible risk? Lupus. 2005;14:391-398.
13. Buyon JP, Petri M, Kim MY, Kalunian KC, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:962.
14. Petri M, Kim MY, Kalunian KC, et al. Combined oral contraceptives in women with systemic lupus erythematosus. N Engl J Med. 2005;353: 2550-2558.
15. Walker SE, Allen SH, Hoffman RW, et al. Prolactin: a stimulator of disease activity in systemic lupus erythematosus. Lupus. 1995;4: 3-9.
16. Hrycek A, Pochopien-Kenig G, Scieszka J. Selected acute phase proteins and interleukin-6 in systemic lupus erythematosus patients treated with low doses of quinagolide. Autoimmunity. 2007;40:217-222.
17. McMurray RW, Keisler D, Izui S, et al. Effects of parturition, suckling and pseudopregnancy on variables of disease activity in the B/W mouse model of systemic lupus erythematosus [see comments]. J Rheumatol. 1993;20:1143-1151.
18. Walker SE. Treatment of systemic lupus erythematosus with bromocriptine. Lupus. 2001;10:197-202.
19. Walker SE, Miller D, Hill DL, et al. Prolactin, a pituitary hormone that modifies immune responses. Proceedings of the Mini-symposium on Prolactin and SLE, held at the 5th International Conference on Systemic Lupus Erythematosus, Cancun, Mexico. Lupus. 1998;7:371-375.
20. Jara LJ, Vera-Lastra O, Miranda JM, et al. Prolactin in human systemic lupus erythematosus. Lupus. 2001;10:748-756.
21. Lin Ling, Lin Xia-hong, hunag Zi-yang, et al. The relationship between prolactin and th1/th2 cytokines balance and the modulatory mechanism mediated by prolactin/prolactin receptor pathway in human autoimmune disease. Lupus. 2007;14:Abstract CS0206.
22. Cohen-Solal JF, Jeganathan V, Grimaldi CM, et al. Sex hormones and SLE: influencing the fate of autoreactive B cells. Curr Top Microbiol Immunol. 2006;305:67-88.
23. Grimaldi CM, Hill L, Xu X, et al. Hormonal modulation of B cell development and repertoire selection. Mol Immunol. 2005;42:811- 820.
24. Peeva E, Venkatesh J, Diamond B. Tamoxifen blocks estrogen-induced B cell maturation but not survival. J Immunol. 2005;175: 1415-1423.
25. Rider V, Abdou NI. Gender differences in autoimmunity: molecular basis for estrogen effects in systemic lupus erythematosus. Int Immuno-pharmacol. 2001;1:1009-1024.
26. Buyon JP, Petri MA, Kim MY, et al. The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial. Ann Intern Med. 2005;142:953-962.
27. Petri M. Exogenous estrogen in systemic lupus erythematosus: oral contraceptives and hormone replacement therapy. Lupus. 2001;10:222-226.
28. Lahita RG, Bradlow HL, Kunkel HG, et al. Increased oxidation of testosterone in systemic lupus erythematosus. Arth Rheum. 1983;26: 1517-1521.
29. Lahita RG, Bradlow HL, Fishman J, et al. Abnormal estrogen and androgen metabolism in the human with systemic lupus erythematosus. Am J Kidney Dis. 1982;2(1 suppl 1):206-211.
30. Oktenli C, Yesilova Z, Kocar IH, et al. Study of autoimmunity in Klinefelter's syndrome and idiopathic hypogonadotrpohic hypogonadism. J Clin Immunol. 2002;22:137-143.
31. Petri MA, Lahita RG, Van Vollenhoven RF, et al. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum. 2002;46:1820-1829.
32. Petri MA, Mease PJ, Merrill JT, et al. Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum. 2004;50:2858-2868.